Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

Clara Montagut, MD, Guillem Argilés, MD, Fortunato Ciardiello, MD,  Thomas T. Poulsen, PhD, Rodrigo Dienstmann, MD, Michael Kragh, PhD, Scott Kopetz, MD, Trine Lindsted, PhD, Cliff Ding, PhD, Joana Vidal, MD, Jenifer Clausell-Tormos, PhD, Giulia Siravegna, PhD, Francisco J. Sánchez-Martín, PhD, Klaus Koefoed, PhD, Mikkel W. Pedersen, PhD, Michael M. Grandal, PhD, Mikhail Dvorkin, MD, Lucjan Wyrwicz, MD, Ana Rovira, PhD, Antonio Cubillo, MD, Ramon Salazar, MD, Françoise Desseigne, MD, Cristina Nadal, MD, Joan Albanell, MD, Vittorina Zagonel, MD, Salvatore Siena, MD, Guglielmo Fumi, MD, Giuseppe Rospo, PhD, Paul Nadler, MD, Ivan D. Horak, MD, Alberto Bardelli, PhD, Josep Tabernero, MD

JAMA Oncol. Published online February 8, 2018. doi:10.1001/jamaoncol.2017.5245

Poulsen TT, Grandal MM, Skartved NJØ, Hald R, Alifrangis L, Koefoed K, Lindsted T, Fröhlich C, Pollmann SE, Eriksen KW, Dahlman A, Jacobsen HJ, Bouquin T, Pedersen MW, Horak ID, Lantto J, Kragh M.
Clin Cancer Res. 2017 Jul 5. pii: clincanres.0782.2017. doi: 10.1158/1078-0432.CCR-17-0782. [Epub ahead of print]
PMID: 28679766 [PubMed - as supplied by publisher]

Similar articles 

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

Jacobsen HJ, Poulsen TT, Dahlman A, Kjær I, Koefoed K, Sen JW, Weilguny D, Bjerregaard B, Andersen CR, Horak ID, Pedersen MW, Kragh M, Lantto J.

Clin Cancer Res. 2015 Sep 15;21(18):4110-22.

Sym004: Truly a New Level of Anti-EGFR Treatment?

Stintzing, S and Heinemann, V.

Cancer Discov; 5(6); 578–80, 2015

A proof of concept trial of the anti‑EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck

Machiels JP1, Specenier P, Krauß J, Dietz A, Kaminsky MC, Lalami Y, Henke M, Keilholz U, Knecht R, Skartved NJ, Horak ID, Pamperin P, Braun S, Gauler TC.

Cancer Chemother Pharmacol. 2015 Jul;76(1):13-20

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance

Pedersen MW, Jacobsen HJ, Koefoed K, Dahlman A, Kjær I, Poulsen TT, Meijer PJ, Nielsen LS, Horak ID, Lantto J, Kragh M

AACR, 2015

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Robak T, Windyga J, Trelinski J, von Depka Prondzinski M, Giagounidis A, Doyen C, Janssens A, Álvarez-Román MT, Jarque I, Loscertales J, Rus GP, Hellmann A, Jedrzejczak WW, Kuliczkowski K, Golubovic LM, Celeketic D, Cucuianu A, Gheorghita E, Lazaroiu M, Shpilberg O, Attias D, Karyagina E, Svetlana K, Vilchevska K, Cooper N, Talks K, Prabhu M, Sripada P, Bharadwaj TPR, Næsted H, Skartved NJØ, Frandsen TP, Flensburg MF, Andersen PS, Petersen J

Blood, 2012, 120, 3627-3628

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, Haurum J, Jensen A, Kragh M, Andersen PS, Pedersen MW

Landes Bioscience, 2011, 3:6, 584-595

Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans.

Poulsen TR, Jensen A, Haurum JS, Andersen PS

J Immunol., 2011, 187:8, 4229-4235

Preclinical pharmacokinetics and safety of Sym004: A synergistic antibody mixture directed against epidermal growth factor receptor.

Skartved NJ, Jacobsen HJ, Pedersen MW, Jensen PF, Sen JW, Hey A, Kragh M.

Clin Cancer Res., 2011, 17:18, 5962-5972

Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use

Frandsen TP, Naested H, Rasmussen SK, Hauptig P, Wiberg FC, Rasmussen LK, Jensen AM, Persson P, Wikén M, Engström A, Jiang Y, Thorpe SJ, Förberg C, Tolstrup AB.

Biotechnol Bioeng., 2011, 108:9, 2171-2181

Capturing the Natural Diversity of the Human Antibody Response against Vaccinia Virus

Lantto J, Hansen MH, Rasmussen SK, Steinaa L, Poulsen TR, Duggan J, Dennis M, Naylor I, Easterbrook L, Bregenholt S, Haurum J, Jensen A.

J.Virology, 2011, 85:4, 1820-1833

Development of Mass Spectrometry Based Techniques for the Identification and Determination of Compositional Variability in Recombinant Polyclonal Antibody Products

Persson P, Rasmussen LK, Holmberg E, Frandsen TP.

Anal.Chem., 2010, 82, 7272-7282

Single-Batch Production of Recombinant Human Polyclonal Antibodies

Nielsen LS, Baer A, Müller C, Gregersen K, Moenster NT, Rasmussen SK, Weilguny D, Tolstrup AB.

Mol Biotechnol, 2010, 45:3, 257-266

Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy

Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS and Kragh M.

Cancer Research, 2010, 70, 588-597

Kinetic, Affinity, and Diversity Limits of Human Polyclonal Antibody Responses against Tetanus Toxoid

Poulsen TR, Meijer PJ, Jensen A, Nielsen LS, Andersen PS.

J Immunol. 2007 Sep 15;179(6):3841-50

Manufacture of recombinant polyclonal antibodies

Rasmussen SK, Rasmussen LK, Weilguny D, Tolstrup AB.

Biotechnol Lett. 2007, Feb 20

Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen

Andersen PS, Haahr-Hansen M, Coljee VW, Hinnerfeldt FR, Varming K, Bregenholt S, Haurum JS.

Mol Immunol. 2007 Jan;44(4):412-22

Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses

Klitgaard JL, Coljee VW, Andersen PS, Rasmussen LK, Nielsen LS, Haurum JS, Bregenholt S.

J Immunol. 2006 Sep 15;177(6):3782-90

Development of recombinant human polyclonal antibodies for the treatment of complex human diseases

Tolstrup AB, Frandsen TP, Bregenholt S.

Expert Opin Biol Ther. 2006 Sep;6(9):905-12. Review

Recombinant polyclonal antibodies: the next generation of antibody therapeutics?

Haurum JS

Drug Discov Today. 2006 Jul;11(13-14):655-660

Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections

Bregenholt S, Jensen A, Lantto J, Hyldig S, Haurum JS

Curr Pharm Des. 2006;12(16):2007-2015

Allergen-specific polyclonal antibodies reduce allergic disease in a mouse model of allergic asthma

Moerch U, Haahr Hansen M, Vest Hansen NJ, Rasmussen LK, Oleksiewicz MB, Frandsen TP, Haurum JS, Bregenholt S.

Int Arch Allergy Immunol. 2006;140(3):261-26

Production of target-specific recombinant human polyclonal antibodies in mammalian cells

Wiberg FC, Rasmussen SK, Frandsen TP, Rasmussen LK, Tengbjerg K, Coljee VW, Sharon J, Yang CY, Bregenholt S, Nielsen LS, Haurum JS, Tolstrup AB.

Biotechnol Bioeng. 2006 Jun 5;94(2):396-405 

Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing

Meijer PJ, Andersen PS, Haahr Hansen M, Steinaa L, Jensen A, Lantto J, Oleksiewicz MB, Tengbjerg K, Poulsen TR, Coljee VW, Bregenholt S, Haurum JS, Nielsen LS.

J Mol Biol. 2006 May 5;358(3):764-72

Characterization of different cell culture media for expression of recombinant antibodies in mammalian cells: Presence of contaminating bovine antibodies

Rasmussun LK, Larsen YB, Højrup P.

Protein Expression and Purification, 2005; 41:373-377

Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle

Haurum J, Bregenholt S.

IDrugs. 2005 May;8(5):404-9. Review

Pathogen-specific recombinant human polyclonal antibodies: biodefence applications

Bregenholt S, Haurum J.

Expert Opin Biol Ther. 2004 Mar;4(3):387-96. Review

Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs.

Zaitseva M, Kapnick SM, Meseda CM, Shotwell E, King LR, Manischewitz J, Scott J, Kodihalli S, Merchlinsky M, Nielsen H, Lantto J, Weir JP, and Golding H. 

J. Virol., 2011, doi:10.1128/JVI.00121-11

Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura.

Stasi R.

Curr Opin Mol Ther. 2010 Dec;12(6):734-40

Symphogen internalized EGFR

Hansen, S., 2010 January 25; A5-A6

Symphogen, Origen develop antibody-producing chickens

Carroll, J., 2009 March 6

Expression of a prototypic anti-colorectal cancer polyclonal antibody library in mammalian cells

Chen L, Liebman MA, Teodorescu-Frumosu S, Schnitzler AC, Sharon J.

Immunol Lett. 2003 Aug 5;88(2):135-140

Polyclonal Fab phage display libraries with a high percentage of diverse clones to Cryptosporidium parvum glycoproteins

Chen L, Williams BR, Yang CY, Cevallos AM, Bhat N, Ward H, Sharon J.

Int J Parasitol. 2003 Mar;33(3):281-291

Construction of polyclonal antibody libraries using phage display

Sharon J, Sompuram SR, Yang CY, Williams BR, Sarantopoulos S.

Methods Mol Biol. 2002;178:101-112. Review

Recombinant polyclonal antibody libraries

Sharon J, Sarantopoulos S, Den W, Kao CY, Baecher-Allan CM, Santora KE, Sompuram SR, Petersen-Mahrt S, Williams BR.

Comb Chem High Throughput Screen. 2000 Jun;3(3):185-196. Review

Generation of a polyclonal fab phage display library to the human breast carcinoma cell line BT-20

Santora KE, Sarantopoulos S, Den W, Petersen-Mahrt S, Sompuram SR, Sharon J.

Comb Chem High Throughput Screen. 2000 Feb;3(1):51-57

Generation of a polyclonal Fab phage display library to the protozoan parasite Cryptosporidium parvum

Baecher-Allan CM, Santora K, Sarantopoulos S, Den W, Sompuram SR, Sharon J, Cevallos AM, Bhat N, Ward H.

Comb Chem High Throughput Screen. 1999 Dec;2(6):319-325

A bidirectional phage display vector for the selection and mass transfer of polyclonal antibody libraries

Den W, Sompuram SR, Sarantopoulos S, Sharon J.

J Immunol Methods. 1999 Jan 1;222(1-2):45-57

A method for linking VL and VH region genes that allows bulk transfer between vectors for use in generating polyclonal IgG libraries

Sarantopoulos S, Kao CY, Den W, Sharon J.

J Immunol. 1994 Jun 1;152(11):5344-5351